| Molecular Formula | C38H38N6O3S |
| Molar Mass | 658.81 |
| Density | 1.50±0.1 g/cm3(Predicted) |
| Melting Point | >161oC (dec.) |
| Solubility | DMSO: ≥ 12 mg/mL |
| Appearance | Solid |
| Color | Pale Yellow to Light Beige |
| pKa | 8.88±0.70(Predicted) |
| Storage Condition | -20°C Freezer |
| Use | A- 1331852 is a BCL-XL-selective inhibitor with oral activity with a Ki value of less than 10 pM. |
| In vitro study | In primary CD34 CML cells, A- 1331852 were able to exert a potent killing effect by administration alone or in combination with TKIs. The low concentration of A- 1331852 was also very effective in inducing apoptosis of the cells, and began to play a role in 1 hour after treatment. |
| In vivo study | A- 1331852 has antitumor effect in Molt-4 transplanted tumor model and can induce tumor regression. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.518 ml | 7.589 ml | 15.179 ml |
| 5 mM | 0.304 ml | 1.518 ml | 3.036 ml |
| 10 mM | 0.152 ml | 0.759 ml | 1.518 ml |
| 5 mM | 0.03 ml | 0.152 ml | 0.304 ml |